Author's reply: the influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
Serri
Omar
O
D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000209:etiology*; D006801:Humans; D006966:Hyperprolactinemia / Q000150:complications*; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications*
D002097:C-Reactive Protein